Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants - Wikidata - awgldk - TriplyDB

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

http://www.wikidata.org/entity/Q28768526

about

Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection Antibodies against viruses: passive and active immunization Monoclonal antibody-based therapies for microbial diseases Therapeutic and prevention strategies against human enterovirus 71 infection Mechanisms of GII.4 norovirus persistence in human populations Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.Discovery of an antibody for pan-ebolavirus therapy Avian influenza virus, Streptococcus suis serotype 2, severe acute respiratory syndrome-coronavirus and beyond: molecular epidemiology, ecology and the situation in China.Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus.Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery.Back to the future: recombinant polyclonal antibody therapeutics.Progress towards recombinant anti-infective antibodies.Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein.Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus.Monoclonal antibodies for prophylaxis and therapy of infectious diseases.Chronic beta-AR activation-induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized female rats.Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends.Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.Bridging the past and the future of virology: surface plasmon resonance as a powerful tool to investigate virus/host interactions.Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics.The SARS-CoV ferret model in an infection-challenge study.Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.Early cytokine mRNA expression profiles predict Morbillivirus disease outcome in ferrets.Animal models and vaccines for SARS-CoV infection.

P2860

Q26863621-46E31731-724D-49B0-AA95-169B39C04A4B Q27324824-24ED8AAC-01A3-4292-B0E4-CFCCF7883A88 Q27489392-0D7BFD5E-B2E9-456B-B702-7FD8FA9F5ECA Q27490830-ECE09436-2366-44DD-AA2F-45D8C0305911 Q28080796-510A926A-B2E9-4859-97D5-AF28D562A032 Q28472177-B888893F-7B7A-49F2-93DE-3CCCF8461DA4 Q30252022-20589D96-49A8-4227-B453-80172298585A Q30377663-65809161-D263-4C7F-BFA6-E245465DC66E Q30385927-52560BA7-1685-45AD-B9EA-A6455D7FFFFB Q31080225-5E107A21-A050-4DD8-9243-F31105D29E55 Q33383237-581572EA-3731-4FD2-B0E7-13299D109368 Q33409160-59980CAB-36F1-434E-933F-DEA38ABEFBA3 Q33412190-9351F81E-ACC9-4DA9-BE68-3AAC8593F5A5 Q33412776-5D08A69E-3AD6-4DBC-A71E-761B5CB89D62 Q33568256-76AEFF91-7B7B-43BC-8874-FFFFEF69E101 Q33627189-1FDF472C-4C9B-45E8-8EDC-128BC138A057 Q33678943-BAD9824C-5517-4AAD-A02B-D544EFC9AA86 Q33685512-6A93D72E-25E9-41D2-9F85-6DC8DD3E7F19 Q34228030-69F2329E-BBF3-49FC-AAB5-4C8C41EF2E25 Q34491357-1166DDF6-8EAE-44DA-A3C1-AF301A7E612E Q34536782-F594D22E-97D1-495A-BB65-C983FDC3E969 Q35019893-05B571BE-257E-4943-BAEE-68EAB17EA628 Q35675647-47F9598A-8B04-41B5-AA41-4E9061E59E0A Q36154930-01AB4E9A-908A-44D1-871E-41A524C64557 Q36498144-7541E6E9-812D-4BCD-A9E1-F356367E494F Q36845879-1A3EEE5A-87DC-41A1-AAF5-ACA57F065CC8 Q36989900-286DA5FD-D862-4BC4-8186-29F02DC6F938 Q37486435-219CC615-EDB2-4826-BBAA-ADD219932109 Q37631303-963AEF55-0EAE-4CF1-B9EC-C2771207EBB2 Q37762275-8B15593D-0700-45E8-8E4D-1F68702628DC Q37929687-E47BD106-FB31-401C-904D-728B947C8665 Q38098075-D4791FBC-72C5-45F2-BA49-8228F39BC5FD Q38141148-E673D0DD-762C-4D26-B4A3-49E73A962074 Q39001735-BE634BA8-57E9-4F62-9CAB-BFFF67FF51E6 Q39370292-976A8D49-C93F-4D9D-830C-64C5DE7CE8AF Q39727842-93F6AEE6-0C8A-4FAF-9B35-E5D352040C29 Q40061368-4986C5E8-9578-4056-A9DA-A726718AA970 Q40083207-F4D6EB50-4246-4C72-AD1A-760CD16BD9E8 Q41453740-91B00651-0373-48B3-8C3D-F27FBAF1C6DA Q43152086-4279F9CB-E425-4957-8047-FCF7F5452468

P2860

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

http://www.wikidata.org/entity/Q28768526

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Human monoclonal antibody comb ...... and coverage of escape mutants

@ast

Human monoclonal antibody comb ...... and coverage of escape mutants

@en

type

label

Human monoclonal antibody comb ...... and coverage of escape mutants

@ast

Human monoclonal antibody comb ...... and coverage of escape mutants

@en

prefLabel

Human monoclonal antibody comb ...... and coverage of escape mutants

@ast

Human monoclonal antibody comb ...... and coverage of escape mutants

@en

P1433

Q28768526-E8EA33F6-0B6A-4743-891D-2A86CD994A91

P1476

Q28768526-7C6B3F80-7717-46AE-956A-A045F0CFAB0B

P2093

Q28768526-0B5DFB17-C383-484F-95FE-AB8F442FB45D

Q28768526-106358E5-F1F6-4CF5-BF84-5D5FABD4B287

Q28768526-43A6B57C-D9C2-4264-845C-CBDF7403C236

Q28768526-4DA46F7E-F8BD-4B40-8EEC-90E476600046

Q28768526-5D138C42-67AC-4472-8653-2510DD33C715

Q28768526-7228F63A-D988-4689-932F-D7309BC538DC

Q28768526-78FF5229-A826-4052-9487-4CBB1B789B58

Q28768526-82F9DCBA-CF67-4A6A-83F1-CD9607E61A4E

Q28768526-8FEBE674-F863-490A-A48D-8E8E5693DE37

Q28768526-A0881CBA-F09A-49AA-B45D-ADA4D5A1A8A5

P2860

Q28768526-0467E6C8-3482-4035-BC2F-138DC554AE18

Q28768526-0A7E08F8-CFEF-4408-B396-1427E7123792

Q28768526-1341B18E-6215-4969-8B38-6F2D436F8D5A

Q28768526-14A52384-5C48-4A24-B6B6-47C3B9C996CE

Q28768526-192C6CA3-D962-49C8-9EF0-EE15B267866C

Q28768526-286BD04B-CF62-4858-8070-AA60D6F22B3E

Q28768526-2F47A0D9-861E-4BAF-8481-B5FCD9F7EE09

Q28768526-312F39FE-D7CC-4DEB-BAC7-08DE03AA83E1

Q28768526-3357C505-AEDC-4E69-8FBC-D979659B2076

Q28768526-34E196A9-949C-4913-8ABD-5C9B4118D350

P304

Q28768526-3E49A3EE-E072-40B6-A60B-9BA00B2145F1

P31

Q28768526-20059E18-9ADB-4021-A39F-D75FB259818F

P356

Q28768526-945E0218-E182-47F1-BFB1-167140233EFA

P407

Q28768526-FE4B0458-FED3-4B91-98FE-F9A67153C09C

P433

Q28768526-376AE6AF-A9C9-4BCB-A38C-C87BF83DAF43

P478

Q28768526-B38E41F1-49C8-48A6-A0D8-B46C214855EF

P50

Q28768526-55C72567-915C-4095-890E-FF479B94185C

Q28768526-65274264-C850-4936-AACC-E36A393460CD

Q28768526-89E5C338-E72A-461A-8504-6121A6354545

P577

Q28768526-8CACA77D-04F1-4C5D-BBCB-865EE1C02C6F

P5875

Q28768526-AF3A5F94-AACC-4B65-9EFD-CD72F5A71A4F

P698

Q28768526-F41BBEF1-3E8D-446C-919E-ECCFD2AD55A3

P921

Q28768526-4F0E5161-3C05-4B33-B8B0-F0E80346175D

Q28768526-BF9B81A6-C33A-42EF-87C2-F80212B82CAD

Q28768526-F9F430EF-DEC5-4143-B775-5F9A319F3810

P932

Q28768526-5644EC69-1BD6-4E7B-9B95-3778D3502CE5

P356

JOURNAL.PMED.0030237

P1433

P1476

Human monoclonal antibody comb ...... and coverage of escape mutants

@en

P2093

Arjen Q Bakker

http://www.w3.org/2001/XMLSchema#string

Chung Y Cheung

http://www.w3.org/2001/XMLSchema#string

Cynthia S W Leung

http://www.w3.org/2001/XMLSchema#string

Edward N van den Brink

http://www.w3.org/2001/XMLSchema#string

Els van Deventer

http://www.w3.org/2001/XMLSchema#string

Freek Cox

http://www.w3.org/2001/XMLSchema#string

Hans Wilhelm Doerr

http://www.w3.org/2001/XMLSchema#string

Jan ter Meulen

http://www.w3.org/2001/XMLSchema#string

Johannes A Bogaards

http://www.w3.org/2001/XMLSchema#string

John de Kruif

http://www.w3.org/2001/XMLSchema#string

P2860

CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus

Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

SARS transmission pattern in Singapore reassessed by viral sequence variation analysis

Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus

Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

P304

e237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PMED.0030237

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Leo Lit Man Poon

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6988951

http://www.w3.org/2001/XMLSchema#string

P698

16796401

http://www.w3.org/2001/XMLSchema#string

P921

severe acute respiratory syndrome-related coronavirus

severe acute respiratory syndrome coronavirus

P932

1483912

http://www.w3.org/2001/XMLSchema#string